HRTS
Tema Heart & Health ETF
HRTS seeks to provide investors with exposure to companies that are focused on developing treatments and solutions for obesity and cardiometabolic conditions.
US
EQUITY
Active
MANAGEMENT STYLE
$ 50.0 M
ASSETS UNDER MGMT
75 bp
EXPENSES
Fund Basics
| Inception date | Nov 20, 2023 |
| Regulation | Open-Ended Fund |
| Fund Website | link... |
| Distributions | Annually |
| Currency | USD |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | No |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
Complete list +
| ELI LILLY & CO | 11.5 % |
| UNITEDHEALTH GROUP INC | 5.2 % |
| NOVO NORDISK A/S-B | 5.2 % |
| ROCHE HOLDINGS LTD-SPONS ADR | 4.5 % |
| MERCK & CO. INC. | 4.3 % |
| THERMO FISHER SCIENTIFIC INC | 4.0 % |
| ASTRAZENECA PLC | 4.0 % |
| JOHNSON & JOHNSON | 3.6 % |
| GILEAD SCIENCES INC | 3.4 % |
| NOVARTIS AG | 3.4 % |
Constituent Breakdown
| Number of holdings | 42 |
| Herfindahl-Hirschman Index | 368 |
| Wgt avg mkt cap (mns) | $254,048 |
| Large cap (>$10bn) | 92.0% |
| Mid cap ($2-10bn) | 6.5% |
| Small cap (<$2bn) | 0.3% |
| Developed mkts. | 97.2% |
| Emerging mkts. | 0.0% |
Sector Breakdown
Country Exposure
 |
UNITED STATES | 74.7 % |
 |
SWITZERLAND | 7.9 % |
 |
DENMARK | 6.5 % |
 |
BRITAIN | 4.0 % |
 |
ISRAEL | 2.1 % |
 |
IRELAND | 1.9 % |
 |
JAPAN | 1.3 % |
Historical Performance
Standardized Performance (as of 05/31/2026)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | -2.7% | 23.6% | 3.7% | -- | -- | -- | -- | 10.6% |
| Dividend Yield | 0.0% | 1.7% | 1.5% | -- | -- | -- | -- | 1.3% |
| Total Returns | -2.7% | 25.3% | 5.2% | -- | -- | -- | -- | 11.9% | Ann. Volatility | 16.3% | 15.9% | 18.8% | -- | -- | -- | -- | 19.1% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 0.65 | 23% |
| MSCI EAFE | 0.63 | 35% |
| MSCI Emg Mkts | 0.32 | 16% |
Liquidity Measures
| Avg. volume (000) | 4 |
| ADV traded (mns) | $0 |
| Turnover | 0.3% |
| Avg. Bid/Ask (% of price) | 0.31% |
Technical Indicators
| 30d moving avg. (EMA) | $33.89 |
| Relative strength (RSI) | 52 |
| MACD/Signal | 0.15/0.05 |
| Bollinger Bands (Upper/Lower) | $34.56/$33.05 |
| Short interest (% of AUM) | 0.0% |
Distributions
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. HRTS |
Expenses vs. HRTS |
ALTAR Score™ vs. HRTS |
|---|---|---|---|---|
| IXJ | iShares Global Healthcare ETF | 54.6% | -33 bp | +3.7% |
| FHLC | Fidelity MSCI Health Care Index ETF | 53.2% | -67 bp | +2.6% |
| XLV | Health Care Select Sector SPDR | 53.2% | -67 bp | +3.9% |
| IYH | iShares U.S. Healthcare ETF | 52.7% | -35 bp | +3.1% |
| VHT | Vanguard Health Care ETF | 52.4% | -66 bp | +2.3% |
| GDOC | Goldman Sachs Future Health Care Equity ETF | 41.9% | 0 bp | -1.9% |
| CANC | Tema Oncology ETF | 36.9% | 0 bp | -5.5% |
| HART | IQ Healthy Hearts ETF | 36.3% | -30 bp | +2.7% |
| BMED | Future Health ETF | 34.8% | +10 bp | -2.4% |
| MEDX | Horizon Kinetics Medical ETF | 33.4% | +10 bp | -1.9% |
Risk and Returns: HRTS vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates (USD)
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Book value per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2025 | 2026 | 2027 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 6/3/2026
Peer Group Comparison
Sample data. Subscribe for access.
Historical Valuation Trends Sample data. Subscribe for access.
Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
3.4%
ALTAR SCORE™
20nd
PERCENTILE
UNDERWEIGHT
ETFRC RATING
There are 1,399 funds in the US Equity category with an average
ALTAR Score™ of 5.3% and a standard deviation
of 2.1%. HRTS's ALTAR Score™ is approximately -0.9 standard
deviations above the category average. This places HRTS in the 20nd percentile
among funds in the category.
Sell-Side Consensus
$41.03
PRICE TARGET
+23.9%
UPSIDE